227 related articles for article (PubMed ID: 11808750)
1. Antiretoviral therapy and the lipodystrophy syndrome, part 2: concepts in aetiopathogenesis.
Nolan D; John M; Mallal S
Antivir Ther; 2001 Sep; 6(3):145-60. PubMed ID: 11808750
[TBL] [Abstract][Full Text] [Related]
2. Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level.
Nolan D; Hammond E; James I; McKinnon E; Mallal S
Antivir Ther; 2003 Dec; 8(6):617-26. PubMed ID: 14760896
[TBL] [Abstract][Full Text] [Related]
3. Antiretroviral drugs with adverse effects on adipocyte lipid metabolism and survival alter the expression and secretion of proinflammatory cytokines and adiponectin in vitro.
Lagathu C; Bastard JP; Auclair M; Maachi M; Kornprobst M; Capeau J; Caron M
Antivir Ther; 2004 Dec; 9(6):911-20. PubMed ID: 15651750
[TBL] [Abstract][Full Text] [Related]
4. Adipocytes targets and actors in the pathogenesis of HIV-associated lipodystrophy and metabolic alterations.
Gougeon ML; Pénicaud L; Fromenty B; Leclercq P; Viard JP; Capeau J
Antivir Ther; 2004 Apr; 9(2):161-77. PubMed ID: 15134178
[TBL] [Abstract][Full Text] [Related]
5. On the trail of fugitive fat: the chase turns to NRTIs.
Mascolini M
J Int Assoc Physicians AIDS Care; 1999 Oct; 5(10):24-43. PubMed ID: 11366871
[TBL] [Abstract][Full Text] [Related]
6. Current concepts of metabolic abnormalities in HIV patients: focus on lipodystrophy.
Kolter DP
AIDS Read; 2003 Dec; 13(12 Suppl):S5-13. PubMed ID: 14959694
[TBL] [Abstract][Full Text] [Related]
7. Impact of antiretroviral choice on hypercholesterolaemia events: the role of the nucleoside reverse transcriptase inhibitor backbone.
Jones R; Sawleshwarkar S; Michailidis C; Jackson A; Mandalia S; Stebbing J; Bower M; Nelson M; Gazzard BG; Moyle GJ
HIV Med; 2005 Nov; 6(6):396-402. PubMed ID: 16268821
[TBL] [Abstract][Full Text] [Related]
8. Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.
Joly V; Yeni P
Antivir Ther; 2005; 10(1):29-40. PubMed ID: 15751761
[TBL] [Abstract][Full Text] [Related]
9. Microarray analysis during adipogenesis identifies new genes altered by antiretroviral drugs.
Pacenti M; Barzon L; Favaretto F; Fincati K; Romano S; Milan G; Vettor R; Palù G
AIDS; 2006 Aug; 20(13):1691-705. PubMed ID: 16931933
[TBL] [Abstract][Full Text] [Related]
10. Cutaneous toxicities of antiretroviral therapy for HIV: part I. Lipodystrophy syndrome, nucleoside reverse transcriptase inhibitors, and protease inhibitors.
Introcaso CE; Hines JM; Kovarik CL
J Am Acad Dermatol; 2010 Oct; 63(4):549-61; quiz 561-2. PubMed ID: 20846563
[TBL] [Abstract][Full Text] [Related]
11. Pathogenesis of lipodystrophy and lipid abnormalities in patients taking antiretroviral therapy.
Mallon PW
AIDS Rev; 2007; 9(1):3-15. PubMed ID: 17474309
[TBL] [Abstract][Full Text] [Related]
12. The role of nucleoside reverse transcriptase inhibitors in the fat redistribution syndrome.
Nolan D; Mallal S
J HIV Ther; 2004 May; 9(2):34-40. PubMed ID: 15238874
[TBL] [Abstract][Full Text] [Related]
13. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy.
Brinkman K; Smeitink JA; Romijn JA; Reiss P
Lancet; 1999 Sep; 354(9184):1112-5. PubMed ID: 10509516
[TBL] [Abstract][Full Text] [Related]
14. In combination, nucleoside reverse transcriptase inhibitors have significant effects on 3T3-L1 adipocyte lipid accumulation and survival.
Kosmiski LA; Miller HL; Klemm DJ
Antivir Ther; 2006; 11(2):187-95. PubMed ID: 16640100
[TBL] [Abstract][Full Text] [Related]
15. Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease.
Vigouroux C; Gharakhanian S; Salhi Y; Nguyên TH; Adda N; Rozenbaum W; Capeau J
Diabetes Metab; 1999 Nov; 25(5):383-92. PubMed ID: 10592860
[TBL] [Abstract][Full Text] [Related]
16. Cell culture models for the investigation of NRTI-induced mitochondrial toxicity. Relevance for the prediction of clinical toxicity.
Höschele D
Toxicol In Vitro; 2006 Aug; 20(5):535-46. PubMed ID: 16406476
[TBL] [Abstract][Full Text] [Related]
17. Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity.
Moyle G
Clin Ther; 2000 Aug; 22(8):911-36; discussion 898. PubMed ID: 10972629
[TBL] [Abstract][Full Text] [Related]
18. Antiretroviral therapy with or without protease inhibitors impairs postprandial TAG hydrolysis in HIV-infected men.
Ware LJ; Jackson AG; Wootton SA; Burdge GC; Morlese JF; Moyle GJ; Jackson AA; Gazzard BG
Br J Nutr; 2009 Oct; 102(7):1038-46. PubMed ID: 19480729
[TBL] [Abstract][Full Text] [Related]
19. Complications associated with NRTI therapy: update on clinical features and possible pathogenic mechanisms.
Nolan D; Mallal S
Antivir Ther; 2004 Dec; 9(6):849-63. PubMed ID: 15651744
[TBL] [Abstract][Full Text] [Related]
20. Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study.
Young J; Rickenbach M; Weber R; Furrer H; Bernasconi E; Hirschel B; Tarr PE; Vernazza P; Battegay M; Bucher HC
Antivir Ther; 2005; 10(1):73-81. PubMed ID: 15751765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
